Pyelonephritis adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 8,465 adverse event reports that record the MedDRA preferred term Pyelonephritis. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 527 reports in the 12 months to June 2026 and 524 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 957 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 527 (under 0.1%) record this term. Reports for female patients were 66.8% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 109 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Pyelonephritis name as a suspect product, in order of name
Drug	Class	Reports with this term
Abatacept	Selective T cell costimulation modulator	37
Actemra	Interleukin-6 receptor antagonist	114
Adalimumab	Tumor necrosis factor blocker	31
Amoxicillin	Penicillin-class antibacterial	26
Aspirin	Nonsteroidal anti-inflammatory drug	26
Atezolizumab	Programmed death Receptor-1 blocking antibody	50
Atorvastatin		31
Avastin	Vascular endothelial growth factor inhibitor	35
Avonex	Interferon beta	65
Azathioprine	Purine antimetabolite	78
Basiliximab	Interleukin-2 receptor blocking antibody	32
Bevacizumab	Vascular endothelial growth factor inhibitor	73
Bortezomib	Proteasome inhibitor	27
Carboplatin	Platinum-based drug	132
Ceftriaxone	Cephalosporin antibacterial	25
CellCept	Antimetabolite immunosuppressant	67
Certolizumab pegol	Tumor necrosis factor blocker	47
Cimzia	Tumor necrosis factor blocker	60
Ciprofloxacin	Fluoroquinolone antibacterial	68
Cisplatin	Platinum-based drug	66
Clonazepam	Benzodiazepine	25
Clozapine	Atypical antipsychotic	33
Clozaril	Atypical antipsychotic	37
Cosentyx	Interleukin-17A antagonist	117
Cyclophosphamide	Alkylating drug	150
Cyclosporine	Calcineurin inhibitor immunosuppressant	127
Dapagliflozin	Sodium-Glucose cotransporter 2 inhibitor	57
Dexamethasone	Corticosteroid	142
Diclofenac	Nonsteroidal anti-inflammatory drug	34
Docetaxel	Microtubule inhibitor	44
Eliquis	Factor Xa inhibitor	26
Enbrel	Tumor necrosis factor blocker	177
Enfortumab vedotin		38
Esomeprazole	Proton pump inhibitor	37
Etanercept	Tumor necrosis factor blocker	27
Etoposide	Topoisomerase inhibitor	73
Everolimus	Kinase inhibitor	43
Farxiga	Sodium-Glucose cotransporter 2 inhibitor	25
Fluorouracil	Nucleoside metabolic inhibitor	41
Forteo	Parathyroid hormone analog	36
Forxiga		40
Fosamax	Bisphosphonate	67
Furosemide	Loop diuretic	34
Gilenya	Sphingosine 1-phosphate receptor modulator	36
Humira		214
Hydroxychloroquine	Antimalarial	36
Ibuprofen	Nonsteroidal anti-inflammatory drug	45
Inflectra	Tumor necrosis factor blocker	33
Infliximab	Tumor necrosis factor blocker	76
Invokana	Sodium-Glucose cotransporter 2 inhibitor	82
Januvia	Dipeptidyl peptidase 4 inhibitor	29
Jardiance	Sodium-Glucose cotransporter 2 inhibitor	88
Keytruda	Programmed death Receptor-1 blocking antibody	113
Lansoprazole	Proton pump inhibitor	39
Leflunomide	Antirheumatic agent	65
Letrozole	Aromatase inhibitor	36
Levofloxacin	Fluoroquinolone antibacterial	27
Lyrica		59
Metformin	Biguanide	60
Methotrexate	Folate analog metabolic inhibitor	298
Methotrexate sodium	Folate analog metabolic inhibitor	43
Methylprednisolone	Corticosteroid	139
Mirena	Progestin	29
Mirtazapine		43
Mycophenolate mofetil	Antimetabolite immunosuppressant	336
Mycophenolic acid	Antimetabolite immunosuppressant	53
Nexium	Proton pump inhibitor	52
Nexium 24HR	Proton pump inhibitor	41
Nivolumab	Programmed death Receptor-1 blocking antibody	37
Nuvaring	Estrogen	38
Ocrelizumab	CD20-directed cytolytic antibody	36
Ocrevus	CD20-directed cytolytic antibody	65
Omalizumab	Anti-IgE	55
Omeprazole	Proton pump inhibitor	96
Opdivo	Programmed death Receptor-1 blocking antibody	31
Orencia	Selective T cell costimulation modulator	60
Paclitaxel	Microtubule inhibitor	87
Pantoprazole	Proton pump inhibitor	86
Pantoprazole sodium	Proton pump inhibitor	44
Pembrolizumab	Programmed death Receptor-1 blocking antibody	40
Prednisolone	Corticosteroid	194
Prednisone	Corticosteroid	261
Prevacid	Proton pump inhibitor	106
Prevacid 24 HR	Proton pump inhibitor	48
Prilosec	Proton pump inhibitor	46
Prograf	Calcineurin inhibitor immunosuppressant	87
Rebetol		33
Rebif	Interferon beta	34
Remicade	Tumor necrosis factor blocker	123
Revlimid	Thalidomide analog	36
Ribavirin	Nucleoside analog antiviral	43
Rinvoq	Janus kinase inhibitor	58
Rituximab	CD20-directed cytolytic antibody	256
Simponi	Tumor necrosis factor blocker	134
Sirolimus	Kinase inhibitor	31
Soliris	Complement inhibitor	49
Stelara	Interleukin-12 antagonist	58
Sulfasalazine	Aminosalicylate	67
Tacrolimus	Calcineurin inhibitor immunosuppressant	380
Tecfidera		50
Tocilizumab	Interleukin-6 receptor antagonist	48
Tysabri	Integrin receptor antagonist	125
Vedolizumab	Integrin receptor antagonist	62
Velcade	Proteasome inhibitor	35
Vincristine		57
Xarelto	Factor Xa inhibitor	33
Xeljanz	Janus kinase inhibitor	31
Xolair	Anti-IgE	57
Zometa		37

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 43 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Pyelonephritis name, in order of name
Class	Reports with this term
Alkylating drug	225
Aminosalicylate	75
Anti-IgE	112
Antimalarial	77
Antimetabolite immunosuppressant	476
Antirheumatic agent	67
Aromatase inhibitor	52
Atypical antipsychotic	149
Benzodiazepine	55
Biguanide	112
Bisphosphonate	102
Calcineurin inhibitor immunosuppressant	637
CD20-directed cytolytic antibody	408
Complement inhibitor	67
Corticosteroid	845
Factor Xa inhibitor	70
Fluoroquinolone antibacterial	102
Folate analog metabolic inhibitor	343
GLP-1 receptor agonist	59
Integrin receptor antagonist	198
Interferon beta	109
Interleukin-12 antagonist	77
Interleukin-17A antagonist	120
Interleukin-6 receptor antagonist	166
Janus kinase inhibitor	134
Kinase inhibitor	299
Microtubule inhibitor	134
Nonsteroidal anti-inflammatory drug	157
Nucleoside metabolic inhibitor	142
Opioid agonist	77
Penicillin-class antibacterial	51
Platinum-based drug	212
Programmed death Receptor-1 blocking antibody	297
Proteasome inhibitor	73
Proton pump inhibitor	649
Purine antimetabolite	90
Selective T cell costimulation modulator	97
Sodium-Glucose cotransporter 2 inhibitor	274
Sphingosine 1-phosphate receptor modulator	50
Thalidomide analog	61
Topoisomerase inhibitor	99
Tumor necrosis factor blocker	729
Vascular endothelial growth factor inhibitor	113

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Pyelonephritis, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Pyelonephritis
Age	Reports	Share
Under 2	78	0.9%
2 to 11	105	1.2%
12 to 17	95	1.1%
18 to 44	1,459	17.2%
45 to 64	2,243	26.5%
65 to 74	1,227	14.5%
75 and over	977	11.5%
Age not given	2,281	26.9%

Sex of the patient in the reports that record Pyelonephritis
Sex	Reports	Share
Female	5,658	66.8%
Male	1,982	23.4%
Unknown or not given	825	9.7%

Age and sex are as the report gives them. 27.8% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Pyelonephritis: adverse event reports that record this term. https://reportedreactions.com/reaction/pyelonephritis/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Pyelonephritis mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page